Cempra (CEMP) Falls: Stock Plunges 10.7%

Zacks Equity Research

Cempra, Inc. (CEMP) saw a big move last session, as the company’s shares fell nearly 11% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.

This pharmaceutical company has seen a flat track record when it comes to current year estimate revisions, as there has been no revision on either side over the past few weeks. The consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

CEMP currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%

Some better-ranked stocks in the Med –Drugs industry include Endocyte, Inc. (ECYT), Salix Pharmaceuticals Ltd. (SLXP) and AcelRx Pharmaceuticals, Inc. (ACRX). While  Endocyte, and Salix Pharmaceuticals carry  a Zacks Rank #1 (Strong Buy), AcelRx Pharmaceuticals holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

 




CEMPRA INC (CEMP): Free Stock Analysis Report


Zacks Investment Research